FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to immunology. Claimed are versions of applying versions of sets of genes (pharmacodynamic (PD) markers) with increased regulation of expression or action, induced by alpha interferon (αIFN). Described are versions of method of identifying patients for obtaining MEDI-545 by identification of such profiles of expression of αIFN-induced FD markers.
EFFECT: application of invention ensures identification of patients, for which treatment with neutralising antibody MEDI-545 can be really effective, which can be applied in medicine.
10 cl, 90 dwg, 33 tbl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING SCLERODERMA | 2008 |
|
RU2530561C2 |
| TEST SYSTEM FOR QUANTITATIVE DIAGNOSTICS OF HUMAN MRNA OF MXA, OAS1, EIF2AK2 GENES BASED ON PCR | 2022 |
|
RU2811690C1 |
| USING VECTOR FOR REDUCING IMMUNE RESPONSE IN VIRAL DELIVERY OF AIPL1 | 2023 |
|
RU2818342C1 |
| EUKARYOTIC CELL LINE | 2018 |
|
RU2776531C2 |
| ANIMALS RESISTANT TO PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | 2012 |
|
RU2644673C2 |
| 5-PIPERIDIN-8-CYANOCHINOLINE DERIVATIVES | 2014 |
|
RU2671496C2 |
| DIAGNOSTICS METHOD USING HNL | 2015 |
|
RU2758608C2 |
| INDUCTION MEDIUM AND METHODS OF STEM CELL CULTIVATION AND THERAPY | 2015 |
|
RU2717983C2 |
| MUTATIONS IN OAS1 GENES | 2006 |
|
RU2465328C2 |
| TYPE I INTERFERON MEDIATED DISORDERS | 2020 |
|
RU2815973C2 |
